The Dutch biotech ProQR $PRQR is spinning out a new biotech called Amylon which will pursue a pipeline of drugs in the CNS space.
Amylon is getting started with a program on beta amyloid related disorders, focusing on RNA-based treatments for a rare genetic disease called Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch type. ProQR vet and CNS expert Thomas de Vlaam is taking the helm as founding CEO.
The company is getting started with some unspecified seed financing from investors. Here’s the scientific advisory crew:
- Thomas Wisniewski, professor of neurology at the New York University School of Medicine,
- Philip Scheltens, professor of neurology at VU University Medical Center Amsterdam and
- Gerard Platenburg, a co-founder at ProQR.
“As part of our corporate strategy to bring as many of our programs to patients as possible, we built ProQR as a group of focused business units that enable us to attract external funding directly into the individual development programs or ultimately spin programs out as we have now done with Amylon,” said Daniel de Boer, the CEO of ProQR. “Through spinning out Amylon, we position the beta amyloid program for optimal success with a dedicated team and the funding to develop treatments for patients suffering from these devastating brain diseases. Through our involvement in the Supervisory board and scientific advisory board of Amylon we will continue to assist Thomas and his team in building success.”
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription